This investigation explored the onset, progression, socioemotional effects, and treatment outcomes of spasmodic dysphonia (SD).
Methods:
A cross-sectional epidemiological approach was used to examine questionnaire responses from 150 individuals with SD.
Results:
Symptoms of SD (mean age at onset, 46 years) began gradually in 76% of cases and were progressive (ie, failed to plateau) in 34% of cases. Botulinum toxin A (Botox) helped to attenuate voice symptoms in 91% of cases; however, the scores on the Voice-Related Quality of Life questionnaire (V-RQOL) were not associated with this effect. The V-RQOL scores improved with time since symptom onset, independent of age and treatment. The patients with only SD experienced onset, course, and progression of symptoms similar to those of the patients with SD and coexisting vocal tremor.
Conclusions:
The symptoms of SD begin gradually and worsen over time. New evidence indicates that SD symptoms may continue to progress without plateau in at least a subset of patients. Individuals with SD and coexisting vocal tremor experience symptom trajectories similar to those of patients with SD only. Although Botox may attenuate voice symptoms, these effects do not appear to be strongly related to the V-RQOL scores. These results provide new and valuable insights regarding the onset, course, progression, and treatment of SD.
BlochCSHiranoMGouldWJ. Symptom improvement of spastic dysphonia in response to phonatory tasks. Ann Otol Rhinol Laryngol1985;94:51–4.
2.
RoyNGouseMMauszyckiSMerrillRMSmithME. Task specificity in adductor spasmodic dysphonia versus muscle tension dysphonia. Laryngoscope2005;115:311–6.
3.
RoyNMauszyckiSCMerrillRMGouseMSmithME. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia. Folia Phoniatr Logop2007;59:83–90.
4.
SimonyanKTovar-MollFOstuniJ. Focal white matter changes in spasmodic dysphonia: A combined diffusion tensor imaging and neuropathological study. Brain2008;131:447–59.
5.
EdgarJDSapienzaCMBidusKLudlowCL. Acoustic measures of symptoms in abductor spasmodic dysphonia. J Voice2001;15:362–72.
6.
LudlowCL. Laryngeal movement disorders: Treatment with botulinum toxin. In: KentRD, ed. The MIT encyclopedia of communication disorders. Cambridge, Mass: The MIT Press, 2004:38–41.
7.
LudlowCL. Treatment for spasmodic dysphonia: Limitations of current approaches. Curr Opin Otolaryngol Head Neck Surg2009;17:160–5.
8.
AronsonAEBrownJRLitinEMPearsonJS. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord1968;33:219–31.
9.
BrodnitzFS. Spastic dysphonia. Ann Otol Rhinol Laryngol1976;85:210–4.
10.
AronsonAE. Clinical voice disorders: An interdisciplinary approach. 3rd ed.New York, NY: Thieme, 1990.
11.
SchaeferSD. Neuropathology of spasmodic dysphonia. Laryngoscope1983;93:1183–204.
12.
IzdebskiKDedoHHBolesL. Spastic dysphonia: A patient profile of 200 cases. Am J Otolaryngol1984;5:7–14.
13.
BhattacharyyaNTarsyD. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg2001;127:389–92.
14.
BenningerMSGardnerGGrywalskiC. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg2001;127:1083–5.
15.
BradenMNJohnsMMIIIKleinAMDelgaudioJMGilmanMHapnerER. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: Clinician and patient perception. J Voice2010;24:242–9.
16.
HogikyanNDWodchisWPSpakCKilenyPR. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice2001;15:576–86.
17.
PanielloRCBarlowJSernaJS. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: Quality of life results. Laryngoscope2008;118:564–8.
18.
RubinADWodchisWPSpakCKilenyPRHogikyanND. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: Part II. Arch Otolaryngol Head Neck Surg2004;130:415–20.
19.
WingateJMRuddyBHLundyDS. Voice handicap index results for older patients with adductor spasmodic dysphonia. J Voice2005;19:124–31.
20.
DedoHH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol1976;85:451–9.
21.
BillerHFSomMLLawsonW. Laryngeal nerve crush for spastic dysphonia. Ann Otol Rhinol Laryngol1979;88:531–2.
22.
NettervilleJLStoneRERaineyCZealearDLOssoffRH. Recurrent laryngeal nerve avulsion for treatment of spastic dysphonia. Ann Otol Rhinol Laryngol1991;100:10–4.
23.
ShiratzkiHFritzellB. Treatment of spasmodic dysphonia by means of resection of the recurrent laryngeal nerve. Acta OtolaryngolSuppl1988;449:115–7.
24.
AronsonAEDe SantoLW. Adductor spastic dysphonia: Three years after recurrent laryngeal nerve resection. Laryngoscope1983;93:1–8.
25.
BillerHFSomMLLawsonW. Laryngeal nerve crush for spastic dysphonia. Ann Otol Rhinol Laryngol1983;92:469.
26.
FritzellBFeuerEHaglundSKnutssonESchiratzkiH. Experiences with recurrent laryngeal nerve section for spastic dysphonia. Folia Phoniatr (Basel)1982;34:160–7.
27.
SercarzJABerkeGSMingYRothschillerJGravesMC. Bilateral thyroarytenoid denervation: A new treatment for laryngeal hyperadduction disorders studied in the canine. Otolaryngol Head Neck Surg1992;107:657–68.
28.
FritzellBHammarbergBSchiratzkiHHaglundSKnutssonEMårtenssonA. Long-term results of recurrent laryngeal nerve resection for adductor spasmodic dysphonia. J Voice1993;7:172–8.
29.
AllegrettoMMorrisonMRammageLLauDP. Selective denervation: Reinnervation for the control of adductor spasmodic dysphonia. J Otolaryngol2003;32:185–9.
30.
BerkeGSBlackwellKEGerrattBRVerneilAJacksonKSSercarzJA. Selective laryngeal adductor denervation-reinnervation: A new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol1999;108:227–31.
31.
ChhetriDKMendelsohnAHBluminJHBerkeGS. Long-term follow-up results of selective laryngeal adductor denervation-reinnervation surgery for adductor spasmodic dysphonia. Laryngoscope2006;116:635–42.
32.
BlitzerA. Spasmodic dysphonia and botulinum toxin: Experience from the largest treatment series. Eur J Neurol2010;17 (suppl 1):28–30.
33.
BrinMFFahnSBlitzerARamigLOStewartC. Movement disorders of the larynx. In: BlitzerABrinMFSasakiCTFahnSHarrisKS, eds. Neurologic disorders of the larynx. New York, NY: Thieme Medical Publishers, 1992:248–78.
34.
CannitoMPWoodsonGEMurryTBenderB. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Otolaryngol Head Neck Surg2004;130:1393–9.
35.
WoodsonGEZwirnerPMurryTSwensonM. Use of flexible fiberoptic laryngoscopy to assess patients with spasmodic dysphonia. J Voice1991;5:85–91.
36.
ZwirnerPMurryTWoodsonGE. Perceptual-acoustic relationships in spasmodic dysphonia. J Voice1993;7:165–71.
37.
RoyNMerrillRMGraySDSmithEM. Voice disorders in the general population: Prevalence, risk factors, and occupational impact. Laryngoscope2005;115:1988–95.
38.
RoyNMerrillRMThibeaultSGraySDSmithEM. Voice disorders in teachers and the general population: Effects on work performance, attendance, and future career choices. J Speech Lang Hear Res2004;47:542–51.
39.
RoyNMerrillRMThibeaultSParsaRAGraySDSmithEM. Prevalence of voice disorders in teachers and the general population. J Speech Lang Hear Res2004;47:281–93.
40.
RoyNStempleJMerrillRMThomasL. Epidemiology of voice disorders in the elderly: Preliminary findings. Laryngoscope2007;117:628–33.
41.
HogikyanNDSethuramanG. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice1999;13:557–69.
42.
WeinbergerMOddoneEZSamsaGPLandsmanPB. Are health-related quality-of-life measures affected by the mode of administration?. J Clin Epidemiol1996;49:135–40.
43.
LeKDNilsenBDietrichsE. Prevalence of primary focal and segmental dystonia in Oslo. Neurology2003;61:1294–6.
44.
LudlowCLAdlerCHBerkeGS. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg2008;139:495–505.
45.
SchwartzSRCohenSMDaileySH. Clinical practice guideline: Hoarseness (dysphonia). Otolaryngol Head Neck Surg2009;141 (suppl 2):S1–S31.
46.
SulicaLLouisED. Clinical characteristics of essential voice tremor: A study of 34 cases. Laryngoscope2010;120:516–28.
47.
LouisEDFordBBarnesLF. Clinical subtypes of essential tremor. Arch Neurol2000;57:1194–8.
48.
AronsonAEHartmanDE. Adductor spastic dysphonia as a sign of essential (voice) tremor. J Speech Hear Disord1981;46:52–8.
49.
BlitzerABrinMFFahnSLovelaceRE. Clinical and laboratory characteristics of focal laryngeal dystonia: Study of 110 cases. Laryngoscope1988;98:636–40.
50.
KendallKALeonardRJ. Interarytenoid muscle Botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. J Voice2011;25:114–9.
51.
SchweinfurthJMBillanteMCoureyMS. Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope2002;112:220–3.
